The role of IL-33 in host response to candida albicans

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Rodriguez Cerdeira C ^a   Lopez Barcenas A ^b   Sanchez Blanco B ^c   Arenas, R ^b  

^a UNIVERSITY OF VIGO   (Spain)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c HOSPITAL DO MEIXOEIRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; CANDIDA ALBICANS; IMMUNE RESPONSE; IMMUNOBIOLOGY; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; REVIEW; TH2 CELL; ANIMAL; CANDIDIASIS; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS; INTERLEUKINS;

EID: 84928207515     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/340690     Document Type: Review

References (56)

1. R. Arenas, Micología Médica Ilustrada, México, Mexico, McGraw-Hill-Interamericana, 4ta edition, 2011.
2. M. G. Netea, G. D. Brown, B. J. Kullberg, and N. A. R. Gow, "An integrated model of the recognition of Candida albicans by the innate immune system, "Nature ReviewsMicrobiology, vol. 6, no. 1, pp. 67-78, 2008.
3. M. G. Netea and L. Maródi, "Innate immune mechanisms for recognition and uptake of Candida species, " Trends in Immunology, vol. 31, no. 9, pp. 346-353, 2010.
4. S. M. Levitz, "Innate recognition of fungal cell walls, " PLoS Pathogens, vol. 6, no. 4, pp. 1-3, 2010.
5. G. D. Brown, J. Herre, D. L. Williams, J. A. Willment, A. S. J. Marshall, and S. Gordon, "Dectin-1 mediates the biological effects of β-glucans, " Journal of ExperimentalMedicine, vol. 197, no. 9, pp. 1119-1124, 2003.
6. G. D. Brown, "Dectin-1: a signalling non-TLR patternrecognition receptor, " Nature Reviews Immunology, vol. 6, no. 1, pp. 33-43, 2006.
7. T. Bürckstümmer, C. Baumann, S. Blüml et al., "An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome, " Nature Immunology, vol. 10, no. 3, pp. 266-272, 2009.
8. T. Fernandes-Alnemri, J. Yu, P. Datta, J. Wu, and E. S. Alnemri, "AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA, " Nature, vol. 458, no. 7237, pp. 509-513, 2009.
9. V. Hornung, A. Ablasser, M. Charrel-Dennis et al., "AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC, " Nature, vol. 458, no. 7237, pp. 514-518, 2009.
10. T. L. Roberts, A. Idris, J. A. Dunn et al., "HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA, " Science, vol. 323, no. 5917, pp. 1057-1060, 2009.
11. P. Broz and D. M. Monack, "Molecular mechanisms of inflammasome activation during microbial infections, " Immunological Reviews, vol. 243, no. 1, pp. 174-190, 2011.
12. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, "Gout-associated uric acid crystals activate the NALP3 inflammasome, " Nature, vol. 440, no. 7081, pp. 237-241, 2006.
13. A. Halle, V. Hornung, G. C. Petzold et al., "The NALP3 inflammasome is involved in the innate immune response to amyloid-β, "Nature Immunology, vol. 9, no. 8, pp. 857-865, 2008.
14. P. Duewell, H. Kono, K. J. Rayner et al., "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, " Nature, vol. 464, no. 7293, pp. 1357-1361, 2010.
15. S. Mariathasan, D. S. Weiss, K. Newton et al., "Cryopyrin activates the inflammasome in response to toxins and ATP, " Nature, vol. 440, no. 7081, pp. 228-232, 2006.
16. O. Gross, H. Poeck, M. Bscheider et al., "Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence, " Nature, vol. 459, no. 7245, pp. 433-436, 2009.
17. A. G. Hise, J. Tomalka, S. Ganesan et al., "An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans, " Cell Host and Microbe, vol. 5, no. 5, pp. 487-497, 2009.
18. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation, " Nature, vol. 469, no. 7329, pp. 221-225, 2011.
19. J. Tomalka, S. Ganesan, E. Azodi et al., "A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans, " PLoS Pathogens, vol. 7, no. 12, Article ID e1002379, 2011.
20. K. Ranta, K. Nieminen, T. Saariaho et al., "Evaluation of fungal extracts to determine immunomodulatory properties, " Journal of Investigational Allergology and Clinical Immunology, vol. 23, no. 4, pp. 226-233, 2013.
21. C. Garcia-Vidal and J. Carratalà, "Pathogenesis of invasive fungal infections, " Enfermedades Infecciosas y Microbiología Clínica, vol. 30, no. 3, pp. 151-158, 2012.
22. S. Kagami, H. L. Rizzo, S. E. Kurtz, L. S. Miller, and A. Blauvelt, "IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans, " Journal of Immunology, vol. 185, no. 9, pp. 5453-5462, 2010.
23. W. P. Arend, G. Palmer, and C. Gabay, "IL-1, IL-18, and IL-33 families of cytokines, " Immunological Reviews, vol. 223, no. 1, pp. 20-38, 2008.
24. C. J. Nile, E. Barksby, P. Jitprasertwong, P. M. Preshaw, and J. J. Taylor, "Expression and regulation of interleukin-33 in human monocytes, " Immunology, vol. 130, no. 2, pp. 172-180.
25. BioCarta-Interleukin-1 (IL-1), http://www.biocarta.com/.
26. M. G. Netea, C. A. A. van der Graaf, A. G. Vonk, I. Verschueren, J. W. M. van der Meet, and B. J. Kullberg, "The role of tolllike receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis, " The Journal of Infectious Diseases, vol. 185, no. 10, pp. 1483-1489, 2002.
27. E. Villamón, D. Gozalbo, P. Roig, J. E. OConnor, D. Fradelizi, and M. L. Gil, "Toll-like receptor-2 is essential in murine defenses against Candida albicans infections, " Microbes and Infection, vol. 6, no. 1, pp. 1-7, 2004.
28. B. N. Gantner, R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill, "Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2, " Journal of Experimental Medicine, vol. 197, no. 9, pp. 1107-1117, 2003.
29. P. N. Pushparaj, D. Li, M. Komai-Koma et al., "Interleukin-33 exacerbates acute colitis via interleukin-4 in mice, " Immunology, vol. 140, no. 1, pp. 70-77, 2013.
30. W. A. Verri Jr., A. T. G. Guerrero, S. Y. Fukada et al., "IL-33mediates antigen-induced cutaneous and articular hypernociception in mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2723-2728, 2008.
31. D. A. C. Magro, M. S. N. Hohmann, S. S. Mizokami et al., "An interleukin-33/ST2 signaling deficiency reduces overt pain-like behaviors in mice, " Brazilian Journal of Medical and Biological Research, vol. 46, no. 7, pp. 601-606, 2013.
32. A. C. Zarpelon, T. M. Cunha, J. C. Alves-Filho et al., "IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E 2, " British Journal of Pharmacology, vol. 169, no. 1, pp. 90-101, 2013.
33. F. Y. Liew, "IL-33: a Janus cytokine, " Annals of the Rheumatic Diseases, vol. 71, supplement 2, pp. i101-i104, 2012.
34. J. Schmitz, A. Owyang, E. Oldhamet al., "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines, " Immunity, vol. 23, no. 5, pp. 479-490, 2005.
35. N. Mato, M. Bando, A. Kusano et al., "Clinical significance of interleukin 33 (il-33) in patients with eosinophilic pneumonia, " Allergology International, vol. 62, no. 1, pp. 45-52, 2013.
36. W. Zhao and Z. Hu, "The enigmatic processing and secretion of interleukin-33, " Cellular and Molecular Immunology, vol. 7, no. 4, pp. 260-262, 2010.
37. D. Talabot-Ayer, C. Lamacchia, C. Gabay, and G. Palmer, "Interleukin-33 is biologically active independently of caspase-33 cleavage, "The Journal of Biological Chemistry, vol. 284, no. 29, pp. 19420-19426, 2009.
38. T. Pecaric-Petkovic, S. A. Didichenko, S. Kaempfer, N. Spiegl, and C. A. Dahinden, "Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 familymember IL-33, " Blood, vol. 113, no. 7, pp. 1526-1534, 2009.
39. J. M. Guzmán-Flores and D. P. Portales-Pérez, "Mechanisms of suppression of regulatory T-cells (Treg), " Gaceta Médica de México, vol. 149, no. 6, pp. 630-638, 2013.
40. H. T. Lee, V. I. G. Tran, W. Kim, J. Kim, H. R. Cho, and B. Kwon, "IL-33 priming regulates multiple steps of the neutrophilmediated anti-Candida albicans response by modulating TLR and dectin-1 signals, " The Journal of Immunology, vol. 189, no. 1, pp. 287-295, 2012.
41. H.-R. Jiang, M. Milovanović, D. Allan et al., "IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages, " European Journal of Immunology, vol. 42, no. 7, pp. 1804-1814, 2012.
42. W. A. Verri Jr., F. O. Souto, S. M. Vieira et al., "IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy, " Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1697-1703, 2010.
43. A. G. Besnard, D. Togbe, N. Guillou, F. Erard, V. Quesniaux, and B. Ryffel, "IL-33-activated dendritic cells are critical for allergic airway inflammation, " European Journal of Immunology, vol. 41, no. 6, pp. 1675-1686, 2011.
44. J. C. Alves-Filho, A. Freitas, F. O. Souto et al., "Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 4018-4023, 2009.
45. A. M. Miller, "Role of IL-33 in inflammation and disease, " Journal of Inflammation, vol. 8, no. 1, article 22, 2011.
46. L. R. Lopetuso, F. Scaldaferri, and T. T. Pizarro, "Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis, " Fibrogenesis and Tissue Repair, vol. 5, no. 1, article 18, 2012.
47. M. Camilleri, K. Madsen, R. Spiller, B. G. Van Meerveld, and G. N. Verne, "Intestinal barrier function in health and gastrointestinal disease, " Neurogastroenterology and Motility, vol. 24, no. 6, pp. 503-512, 2012.
48. A. Fasano, "Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer, " Physiological Reviews, vol. 91, no. 1, pp. 151-175, 2011.
49. A. Fasano, "Leaky gut and autoimmune diseases, " Clinical Reviews in Allergy and Immunology, vol. 42, no. 1, pp. 71-78, 2012.
50. B. M. Peters, G. E. Palmer, A. K. Nash et al., "Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans Vaginitis, " Infection and Immunity, vol. 82, no. 2, pp. 532-543, 2014.
51. S. L. Yu, C. K. Wong, and L. S. Tam, "The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus, " Expert Review of Clinical Immunology, vol. 9, no. 8, pp. 739-749, 2013.
52. A. Roy, G. Ganesh, H. Sippola et al., "Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation, " The Journal Biological Chemistry, vol. 289, no. 1, pp. 237-250, 2014.
53. E. Sundlisæter, R. J. Edelmann, J. Hol et al., "The alarmin IL-33 is a notch target in quiescent endothelial cells, " The American Journal of Pathology, vol. 181, no. 3, pp. 1099-1111, 2012.
54. M. U. Martin, "Special aspects of interleukin-33 and the IL-33 receptor complex, " Seminars in Immunology, vol. 25, no. 6, pp. 449-457, 2013.
55. K. D. Dyer, C. M. Percopo, and H. F. Rosenberg, "IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo, " Immunology Letters, vol. 150, no. 1-2, pp. 41-47, 2013.
56. S. Sattler, H. H. Smits, D. Xu, and F.-P. Huang, "The evolutionary role of the IL-33/ST2 system in host immune defence, " ArchivumImmunologiae etTherapiae Experimentalis, vol. 61, no. 2, pp. 107-117, 2013.